Skip to main content

Table 1 Patients’ characteristics

From: SARS-CoV-2 detection in the lower respiratory tract of invasively ventilated ARDS patients

  Patients (N = 90)
French center (versus Swiss center), n (%) 42 (46.7)
Age, median [IQR] 62.5 [54; 70]
Sex, n (%)
 Male 71 (78.9)
BMI, median [IQR] 29.6 [26; 33.3]
SAPS II at ICU admission, median [IQR] 45.5 [37; 61]
SOFA at ICU admission, median [IQR] 7 [6; 10]
Comorbidities
 Cardiovascular, n (%) 36 (40)
 Chronic respiratory failure, n (%) 18 (20)
 Renal failure, n (%) 14 (15.6)
 Immunosuppression, n (%) 28 (31.1)
 Diabetes mellitus, n (%) 27 (30)
 Cancer, n (%) 4 (4.4)
Treatment administered
 Ritonavir/lopinavir, n (%) 38 (42.2)
 Remdesivir, n (%) 8 (8.9)
 Hydroxychloroquine, n (%) 27 (30)
 Tocilizumab, n (%) 8 (8.9)
 Corticosteroids, n (%) 48 (53.3)
Number of different antibiotics utilized (per patient), median [IQR] 7 [4; 10]
Number of bacteremia per patient, mean (SD) 0.80 (3.92)
Number of VAP per patient, mean (SD) 0.92 (1.05)
Number of LRTS per patient, median [IQR] 3 [2; 4]
Viral load (log10 copies per mL), median [IQR] 3.3 [1.8; 5.2]
Time to negativity in LRTS, median [IQR] 29 [23; 34]
Mortality 6 weeks, n (%) 23 (25.6)
  1. IQR interquartile range, BMI body mass index, SAPS Simplified Acute Physiology Score, SOFA Sequential Organ Failure Assessment score, ICU intensive care unit, LRTS lower respiratory tract samples, SD standard deviation